SINTX Technologies Inc SINT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization
SINTX Technologies Announces Third Quarter 2026 Earnings Release Date and Webcast
SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance
SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts
SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement
SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives
Trading Information
- Previous Close Price
- $1.62
- Day Range
- $1.64–1.64
- 52-Week Range
- $1.40–4.46
- Bid/Ask
- $1.55 / $1.62
- Shares Outstanding
- 7.56M
- Market Cap
- $12.24M
- Volume/Avg
- 1,511 / 114,642
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.84
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
SINTX Technologies Inc is a biomaterials company that develops, manufactures, and commercializes patented and proprietary silicon nitride ceramic biomaterials, composites, devices, and related ceramics technologies for other medical and specialized industrial applications. SINTX has 20 years' experience innovating silicon nitride technologies and operates under a quality management system certified to ISO 13485:2016 and AS9100D, with a product portfolio that includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System for reconstructive surgery, OEM manufacturing of FDA-cleared spinal implants, and its SiNERGY technology platform being developed for biocomposite and 3D printing applications.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 32
- Website
- https://www.sintx.com
Valuation
Metric | SINT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.22 |
Price/Sales | 5.84 |
Price/Cash Flow | — |
Price/Earnings
SINT
Financial Strength
Metric | SINT |
|---|---|
Quick Ratio | 1.32 |
Current Ratio | 2.36 |
Interest Coverage | −291.38 |
Quick Ratio
SINT
Profitability
Metric | SINT |
|---|---|
Return on Assets (Normalized) | −94.81% |
Return on Equity (Normalized) | −273.94% |
Return on Invested Capital (Normalized) | −138.77% |
Return on Assets
SINT
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|<n^F@Y | LOCK|F^L# | $197B | |||
| Medtronic PLC MDT | LOCK|fRg&>rJ | LOCK|dfcgL | $134B | |||
| Stryker Corp SYK | LOCK|?TfQ<w<k | LOCK|X> | $128B | |||
| Boston Scientific Corp BSX | LOCK|$&w@BW& | LOCK|WrVs | $65B | |||
| Edwards Lifesciences Corp EW | LOCK|zs>yh%%! | LOCK|%lFxN | $58B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|>@$@Hfb | LOCK|wM@ | $38B | |||
| DexCom Inc DXCM | LOCK|j!S%PfN | LOCK|dm<$! | $31B | |||
| Koninklijke Philips NV ADR PHG | LOCK|NS | LOCK|Q^^ | $30B | |||
| Steris PLC STE | LOCK|F&@Y@% | LOCK|CdQ&@ | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|L&nQPY! | LOCK|ZB | $20B |
United States